Kourtney Kardashian's Lemme Hit With Class-Action Over "Natural GLP-1" Claims. The Creator-Brand Legal Line Just Moved Again.
Kourtney Kardashian Barker's wellness brand Lemme faces a California class-action lawsuit alleging deceptive marketing on its GLP-1 Daily supplement. The suit is the latest signal that creator-led brands are now held to the same advertising standards as pharma and CPG.
The Creator Economy
Editorial oversight by the Editor-in-Chief
Kourtney Kardashian Barker''s wellness and supplement brand Lemme has been named in a class-action lawsuit filed in California court over the marketing of its Lemme GLP-1 Daily capsule. The suit alleges the company engaged in "deceptive marketing practices" by advertising that consumers would see "un-hunger" and weight-loss benefits from an alleged increase in GLP-1 levels, and that Lemme positioned the supplement as a natural equivalent to prescription GLP-1 drugs (Ozempic, Wegovy, Mounjaro) when the underlying science does not support that comparison. Plaintiffs argue the marketing violates California''s False Advertising Law, Unfair Competition Law, and Consumer Legal Remedies Act.
The suit itself will play out in California court on its merits. The more important read for anyone operating a creator-led brand is what the case signals about where the legal and regulatory line now sits for creator-affiliated CPG products in 2026.
The specific claim under scrutiny
The GLP-1 category is one of the fastest-growing in consumer wellness because the prescription GLP-1 drugs (Ozempic, Wegovy, Mounjaro) have delivered measurable weight-loss outcomes for millions of users. That real-world success has created a huge market for adjacent "natural" or "supplement" products that position themselves as accessible alternatives. The problem is that the underlying pharmacology of prescription GLP-1s is specific, well-characterized, and reproducible. Supplements that market against that comparison but cannot demonstrate the same mechanism or outcomes face immediate regulatory and legal exposure.
Lemme is not the first brand to face this challenge and will not be the last. What makes the Lemme case notable is the audience reach: a Kardashian-branded product carries orders-of-magnitude larger consumer visibility than a generic supplement brand. Which means the class of affected consumers is larger, the plaintiff-side legal interest is stronger, and the reputational exposure for the founder is more severe.
Why this matters for creator-led brands generally
Three implications for any creator running a CPG or supplement business.
One: the same advertising standards that apply to pharmaceutical companies and traditional CPG brands now apply to creator-led brands at scale. "Natural equivalent" comparisons to prescription drugs, "clinically proven" claims without controlled studies, and outcome-based advertising ("see un-hunger") all face the same scrutiny regardless of who owns the brand. The historical assumption that creator brands operated under a different consumer-tolerance standard is dissolving fast, and California courts are the leading edge of that shift.
Two: the marketing copy that drives conversion in social media is exactly the copy that creates legal exposure in false-advertising cases. The specific language that gets clicked on ("un-hunger," "burn fat," "natural equivalent to Ozempic") is the specific language that gets cited in complaints. Creator-brand marketing teams have to reconcile the tension between conversion copy and defensible copy, and the tension is only getting sharper as more of these cases go through court.
Three: the founder personal-brand exposure is real. When a class-action names a supplement company, the coverage almost always foregrounds the celebrity founder because that is what drives clicks. Every consumer-facing story on the Lemme case leads with Kourtney Kardashian''s name, not with the company name. Founders building creator-led brands should expect that pattern and structure the brand-to-founder relationship (equity, licensing, IP, spokesperson agreements) with that in mind.
The regulatory backdrop
This case sits inside a broader tightening of the legal environment for creator-affiliated advertising. The New York S8420A AI synthetic performer disclosure law took effect in June 2026 and requires explicit disclosure when advertising features AI-generated humans. The FTC has updated its endorsement guidance to hold brands responsible for creator claims made about products, and state attorneys general are increasingly bringing consumer-protection cases against creator-affiliated brands where advertising claims outrun the science.
The trajectory is clear. Creator-affiliated commerce is being professionalized on the legal side at the same time it is being professionalized on the operating side. For a longer view on where creator-economy consolidation is heading, see the Compound Creative holding company launch.
What operators should do this week
Three concrete steps for any creator-led CPG, supplement, or wellness brand operating at scale.
First, audit your top-performing marketing copy for outcome-based claims that could be challenged under state false-advertising laws. "Natural equivalent to prescription," "clinically proven," "guaranteed results" are the specific phrases getting flagged. Rewrite to focus on ingredients, quality, and consumer experience without making pharmacological equivalence claims.
Second, revisit your creator-founder legal structure. If the celebrity or creator founder is exposed to personal liability through the marketing copy that the brand generates without their direct review, that risk needs to be addressed in the operating agreement, indemnification structure, and marketing-approval workflow.
Third, invest in the substantiation file for any product-outcome claim you make. If you say the product reduces hunger, you should have consumer study data or clinical evidence that supports the claim. If you cannot generate that data, revise the claim to something that is defensible without it.
The honest read
The Lemme case is not a signal that creator-led brands are more legally exposed than traditional CPG brands. It is a signal that they are equally exposed and that the legal system is now applying the same standards to both. Founders who assumed the creator-affiliation cushion protected them from the enforcement pattern that hit companies like Herbalife, Kellogg, and dozens of other CPG brands over decades are learning the cushion does not exist.
The winners in the next 24 months will be creator-led brands that professionalize their marketing-legal review, build real substantiation for their product claims, and structure the founder-brand relationship in ways that protect both sides of the equation. Everyone else will end up as a case study.
For related coverage on how creator-brand deals are evolving, see our breakdown of AI influencers versus human creators and the influencer selection framework for 2026.
Frequently asked questions
What is the Lemme lawsuit about?
A class-action lawsuit filed in California alleges Kourtney Kardashian''s Lemme brand engaged in deceptive marketing on its GLP-1 Daily supplement by claiming "un-hunger" and weight-loss benefits and positioning the supplement as a natural equivalent to prescription GLP-1 drugs, in alleged violation of California''s False Advertising Law, Unfair Competition Law, and Consumer Legal Remedies Act.
Why does this matter beyond Kourtney Kardashian?
The case signals that creator-led brands are now held to the same advertising and consumer-protection standards as pharmaceutical and traditional CPG brands. The historical assumption that creator brands operated under different consumer-tolerance standards is dissolving.
What should creator-led brand founders do about this?
Audit outcome-based marketing claims, revisit the founder-brand legal structure for personal-liability exposure, and invest in real substantiation for any product-outcome claims. "Natural equivalent to prescription" language is the specific pattern getting flagged.
Are supplements regulated the same as prescription drugs?
No, they are regulated differently by the FDA under the DSHEA framework. But the false-advertising and consumer-protection standards enforced by state attorneys general and civil courts apply regardless of the FDA regulatory category. Marketing claims that outrun the science create legal exposure even when the product is technically a legal supplement.
Does this affect creator marketing partnerships more broadly?
Indirectly, yes. Creators who endorse creator-led CPG products need to think about their own exposure when the brands they promote face false-advertising cases. The FTC has previously named endorsers as parties in enforcement actions when the endorser made specific outcome claims about the product.
By The Creator Economy Editorial Team
Editorial oversight by Ismail Oyekan
Ismail Oyekan is the Editor-in-Chief of The Creator Economy and the founder of IMCX (Influencer Marketing Conference & Expo), the premier industry gathering connecting creators, brands, and capital. Named one of the 100 Most Influential People in Influencer Marketing by Influence Weekly, he has managed over $20 million in influencer marketing budgets and worked with A-list talent including Floyd Mayweather and DJ Khaled. He is a sought-after advisor to creator economy startups.
